Abstract Details

Title Resting State Functional Connectivity Changes of the Pons in Migraine Patients: A Cross-Sectional and Longitudinal Study

Topic Headache

Presentation(s) Headache Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 061

Objective To explore cross-sectional and longitudinal resting state functional connectivity (RS FC) changes of the pons in migraine patients during the interictal phase.

Background

Previous studies support a key role of the dorsal pons in the onset of the migraine attack.

Design/Methods Using a 3.0 Tesla scanner, RS functional magnetic resonance imaging (MRI) and 3D T1-weighted scans were acquired from 91 headache-free episodic migraine patients and 73 controls. Twenty-three migraineurs and 23 controls were reexamined after a mean follow-up (FU) of 4 years. RS FC analysis was performed using a seed-region correlation approach and SPM12.

Results Seventeen patients (74%) reported a decreased number of migraine attacks at follow-up. At baseline, compared to controls, migraine patients showed a decreased RS FC between the left pons and the ipsilateral lingual gyrus and bilateral cerebellum. The left pons had also an increased RS FC with the left precuneus and bilateral orbitofrontal cortex. While, the right pons had a decreased RS FC with the left cerebellum, right fusiform and right inferior temporal gyrus. After 4 years, compared to controls, migraine patients developed a decreased FC between the left pons and the bilateral precuneus. The decreased RS FC between the left pons and ipsilateral cerebellum was associated to less severe and less frequent migraine attacks over the years.

Conclusions Migraine patients experience interictal changes in the functional connections between the pons, pain and visual processing areas. Cerebellar activation is associated to pain perception and inhibition. A decreased RS FC between the pons and cerebellum might reduce the migraine attack frequency and severity over time. RS FC between the pons and precuneus, a region known to play a role in sensory integration and in defining individual pain sensitivity, is initially strengthen, but weaken over time.

Authors/Disclosures
Roberta Messina, MD, PhD (San Raffaele Hospital) PRESENTER	Dr. Messina has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pfizer. Dr. Messina has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pfizer. Dr. Messina has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Lundbeck. Dr. Messina has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Teva. Dr. Messina has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Organon. Dr. Messina has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. Dr. Messina has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eli Lilly.
Paola Valsasina	Paola Valsasina has nothing to disclose.
	No disclosure on file
Massimo Filippi, MD, F�鶹��ýӳ�� (Ospedale San Raffaele, Neuroimaging Research Unit)	Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.
Maria A. Rocca (Neuroimaging Research Unit)	Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen, Bristol Myers Squibb, Eli Lilly, Janssen, Roche. Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AstraZaneca, Biogen, Bristol Myers Squibb, Bromatech, Celgene, Genzyme, Horizon Therapeutics Italy, Merck Serono SpA, Novartis, Roche, Sanofi and Teva. The institution of Maria Assunta Rocca has received research support from MS Society of Canada, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.

�鶹��ýӳ��

�鶹��ýӳ��